Infinity Pharmaceuticals (NASDAQ:INFI) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Infinity Pharmaceuticals (NASDAQ:INFI – Get Rating) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, Piper Sandler reissued a “neutral” rating on shares of Infinity Pharmaceuticals in a report on Friday, February 24th.

Infinity Pharmaceuticals Stock Down 6.6 %

Shares of INFI opened at $0.19 on Friday. The company has a 50-day moving average price of $0.49 and a two-hundred day moving average price of $0.79. The stock has a market cap of $16.52 million, a price-to-earnings ratio of -0.36 and a beta of 1.36. Infinity Pharmaceuticals has a 12 month low of $0.17 and a 12 month high of $1.76.

Institutional Investors Weigh In On Infinity Pharmaceuticals

Several large investors have recently made changes to their positions in INFI. Jane Street Group LLC acquired a new position in Infinity Pharmaceuticals in the fourth quarter valued at about $82,000. Virtu Financial LLC acquired a new position in shares of Infinity Pharmaceuticals in the 4th quarter worth approximately $37,000. Millennium Management LLC boosted its holdings in shares of Infinity Pharmaceuticals by 5.8% in the 4th quarter. Millennium Management LLC now owns 890,128 shares of the biotechnology company’s stock worth $494,000 after acquiring an additional 48,795 shares in the last quarter. Mariner LLC bought a new stake in Infinity Pharmaceuticals during the 4th quarter worth approximately $672,000. Finally, Two Sigma Investments LP increased its holdings in Infinity Pharmaceuticals by 84.2% during the 4th quarter. Two Sigma Investments LP now owns 44,738 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 20,449 shares in the last quarter. Institutional investors own 34.61% of the company’s stock.

About Infinity Pharmaceuticals

(Get Rating)

Infinity Pharmaceuticals, Inc operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development segment. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.